Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Viridian Therapeutics ( (VRDN) ) is now available.
On May 20, 2025, Viridian Therapeutics announced positive long-term durability data from its THRIVE phase 3 clinical trial for veligrotug, an anti-IGF-1R antibody for thyroid eye disease (TED). The trial showed that 70% of patients maintained their response at week 52, with no changes in safety profile. Veligrotug has received Breakthrough Therapy Designation, and the company plans a Biologics License Application submission in the second half of 2025, with a commercial launch anticipated in 2026.
The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.
Spark’s Take on VRDN Stock
According to Spark, TipRanks’ AI Analyst, VRDN is a Underperform.
Viridian Therapeutics is currently facing significant financial hurdles, evident through its declining revenues and persistent losses. The stock’s technical indicators suggest a bearish momentum, further compounded by an unattractive valuation due to negative earnings. However, the recent addition of Jeff Ajer to the board is a strategic positive, potentially bolstering the company’s commercial efforts. Despite this, the overall outlook remains challenging, requiring substantial improvements in financial performance and market execution.
To see Spark’s full report on VRDN stock, click here.
More about Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company based in Waltham, Massachusetts, focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. The company specializes in antibody discovery and protein engineering, advancing multiple candidates for the treatment of thyroid eye disease (TED) and developing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors for autoimmune diseases.
Average Trading Volume: 898,462
Technical Sentiment Signal: Sell
Current Market Cap: $1.05B
For an in-depth examination of VRDN stock, go to TipRanks’ Stock Analysis page.